Three-dimensional dose reconstruction-based pretreatment dosimetric verification in volumetric modulated arc therapy for prostate cancer

We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer. Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS syste...

Full description

Saved in:
Bibliographic Details
Published inRadiation oncology journal Vol. 38; no. 1; pp. 60 - 67
Main Authors Jeong, Yuri, Oh, Jeong Geun, Kang, Jeong Ku, Moon, Sun Rock, Lee, Kang Kyoo
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Society for Radiation Oncology 01.03.2020
대한방사선종양학회
Subjects
Online AccessGet full text
ISSN2234-1900
2234-3156
2234-3164
DOI10.3857/roj.2020.00066

Cover

Abstract We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer. Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD98%, DD2% and DDmean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm. The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DDmean (%) for rectum and bladder. The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer.
AbstractList Purpose: We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer. Materials and Methods: Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD98%, DD2% and DDmean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm. Results: The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DDmean (%) for rectum and bladder. Conclusions: The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer. KCI Citation Count: 0
We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer. Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD98%, DD2% and DDmean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm. The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DDmean (%) for rectum and bladder. The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer.
We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer.PURPOSEWe performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer.Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD98%, DD2% and DDmean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm.MATERIALS AND METHODSPretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD98%, DD2% and DDmean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm.The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DDmean (%) for rectum and bladder.RESULTSThe GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DDmean (%) for rectum and bladder.The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer.CONCLUSIONSThe 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer.
Author Kang, Jeong Ku
Moon, Sun Rock
Jeong, Yuri
Oh, Jeong Geun
Lee, Kang Kyoo
Author_xml – sequence: 1
  givenname: Yuri
  surname: Jeong
  fullname: Jeong, Yuri
– sequence: 2
  givenname: Jeong Geun
  surname: Oh
  fullname: Oh, Jeong Geun
– sequence: 3
  givenname: Jeong Ku
  surname: Kang
  fullname: Kang, Jeong Ku
– sequence: 4
  givenname: Sun Rock
  surname: Moon
  fullname: Moon, Sun Rock
– sequence: 5
  givenname: Kang Kyoo
  surname: Lee
  fullname: Lee, Kang Kyoo
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32229810$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002574012$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp1kkFv1DAQhS1UREvplSPKEQ5ZxnbiJBekqqJQqRISWs6WY09Yt4m92M5K_Qf92XV2lwqQONnyfO-N7TevyYnzDgl5S2HF27r5GPzdigGDFQAI8YKcMcarktNanBz3tAM4JRcx3sHCQC0EvCKnnDHWtRTOyON6ExBLYyd00XqnxsL4iEVA7V1MYdYpn5a9imiKbcAUUKXMpgXLohSsLnYY7GC1WtDCumLnx_lYmryZR5WyWAVdpA0GtX0oBh-ymY8pVwqtnMbwhrwc1Bjx4riekx_Xn9dXX8vbb19uri5vS12xKpU9bYTBqqadUcb0oNlQa-iYxoHWig6cN8hE3UPTMmEo8I5zVAKrVtEeWs7PyYeDrwuDvNdWemX3608v74O8_L6-kZ3oBG9EZj8d2O3cT2h0fnZQo9wGO6nwsFf-XXF2k312sqE0pwDZ4P3RIPhfM8YkJxs1jqNy6OcoWY6RNbwWLKPv_uz13OR3VBlYHQCdPy4GHJ4RCnIZB5nHQS7jIPfjkAXVPwJt0z6jfFc7_k_2BJYgvV0
CitedBy_id crossref_primary_10_1007_s40042_022_00440_y
crossref_primary_10_1016_j_ejmp_2021_09_013
crossref_primary_10_1016_j_radmp_2021_06_001
crossref_primary_10_1097_DM_2024_00010
Cites_doi 10.21037/tro.2018.07.01
10.1118/1.3544657
10.1118/1.598248
10.1002/mp.12810
10.18632/oncotarget.12279
10.1016/j.ejmp.2015.03.017
10.1186/s13014-018-1123-x
10.1200/JCO.2010.31.1217
10.1118/1.3514120
10.1016/j.ejmp.2019.04.014
10.1200/JOP.18.00434
10.1016/j.ejmp.2015.05.016
10.1016/j.ejmp.2014.01.003
10.1186/1748-717X-8-140
10.1118/1.3238104
10.1186/s13014-018-0993-2
10.3857/roj.2018.00122
10.1016/j.ejmp.2017.03.001
10.1118/1.3633904
10.1111/iju.14011
10.1118/1.2890085
10.1259/bjr.20140577
10.1118/1.4767763
ContentType Journal Article
Copyright Copyright © 2020 The Korean Society for Radiation Oncology 2020
Copyright_xml – notice: Copyright © 2020 The Korean Society for Radiation Oncology 2020
DBID AAYXX
CITATION
NPM
7X8
5PM
ACYCR
DOI 10.3857/roj.2020.00066
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Pretreatment QA in prostate cancer VMAT
EISSN 2234-3156
2234-3164
EndPage 67
ExternalDocumentID oai_kci_go_kr_ARTI_9696376
PMC7113150
32229810
10_3857_roj_2020_00066
Genre Journal Article
GrantInformation_xml – fundername: Wonkwang Institute of Clinical Medicine
GroupedDBID 5-W
8JR
8XY
9ZL
AAKDD
AAYXX
ABDBF
ACUHS
ADBBV
AEGXH
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
EF.
GX1
HYE
KQ8
M48
OK1
PGMZT
RPM
ADRAZ
KVFHK
NPM
7X8
5PM
.UV
ACYCR
ID FETCH-LOGICAL-c424t-b176de4519daddb0c2f5c092cef15a1f337e265b07826d103933ea6e48a1b0833
IEDL.DBID M48
ISSN 2234-1900
IngestDate Tue Nov 21 21:21:55 EST 2023
Thu Aug 21 18:13:41 EDT 2025
Fri Jul 11 15:57:01 EDT 2025
Thu Jan 02 22:59:18 EST 2025
Tue Jul 01 01:32:54 EDT 2025
Thu Apr 24 23:00:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Gamma analysis
Intensity-modulated radiotherapy
Prostatic neoplasms
Acceptance criteria
Dose-volume histogram
Pretreatment verification
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c424t-b176de4519daddb0c2f5c092cef15a1f337e265b07826d103933ea6e48a1b0833
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ORCID 0000-0003-0573-3994
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3857/roj.2020.00066
PMID 32229810
PQID 2385273562
PQPubID 23479
PageCount 8
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_9696376
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7113150
proquest_miscellaneous_2385273562
pubmed_primary_32229810
crossref_primary_10_3857_roj_2020_00066
crossref_citationtrail_10_3857_roj_2020_00066
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-03-01
PublicationDateYYYYMMDD 2020-03-01
PublicationDate_xml – month: 03
  year: 2020
  text: 2020-03-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Radiation oncology journal
PublicationTitleAlternate Radiat Oncol J
PublicationYear 2020
Publisher The Korean Society for Radiation Oncology
대한방사선종양학회
Publisher_xml – name: The Korean Society for Radiation Oncology
– name: 대한방사선종양학회
References ref13
ref12
ref15
ref14
ref11
ref10
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref25
ref20
ref22
ref21
Khan (ref3) 2014
ref8
ref7
ref9
ref4
ref6
ref5
References_xml – ident: ref13
  doi: 10.21037/tro.2018.07.01
– ident: ref21
  doi: 10.1118/1.3544657
– ident: ref6
  doi: 10.1118/1.598248
– ident: ref10
  doi: 10.1002/mp.12810
– ident: ref15
  doi: 10.18632/oncotarget.12279
– ident: ref17
  doi: 10.1016/j.ejmp.2015.03.017
– ident: ref20
  doi: 10.1186/s13014-018-1123-x
– ident: ref2
  doi: 10.1200/JCO.2010.31.1217
– ident: ref9
  doi: 10.1118/1.3514120
– ident: ref12
  doi: 10.1016/j.ejmp.2019.04.014
– ident: ref1
  doi: 10.1200/JOP.18.00434
– ident: ref16
  doi: 10.1016/j.ejmp.2015.05.016
– ident: ref18
  doi: 10.1016/j.ejmp.2014.01.003
– ident: ref14
  doi: 10.1186/1748-717X-8-140
– ident: ref8
  doi: 10.1118/1.3238104
– ident: ref11
– ident: ref24
  doi: 10.1186/s13014-018-0993-2
– ident: ref5
  doi: 10.3857/roj.2018.00122
– ident: ref25
  doi: 10.1016/j.ejmp.2017.03.001
– year: 2014
  ident: ref3
– ident: ref22
  doi: 10.1118/1.3633904
– ident: ref4
  doi: 10.1111/iju.14011
– ident: ref7
  doi: 10.1118/1.2890085
– ident: ref19
  doi: 10.1259/bjr.20140577
– ident: ref23
  doi: 10.1118/1.4767763
SSID ssj0000605660
Score 2.177114
Snippet We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated...
Purpose: We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 60
SubjectTerms Original
방사선과학
Title Three-dimensional dose reconstruction-based pretreatment dosimetric verification in volumetric modulated arc therapy for prostate cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/32229810
https://www.proquest.com/docview/2385273562
https://pubmed.ncbi.nlm.nih.gov/PMC7113150
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002574012
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Radiation oncology journal , 2020, 38(1), , pp.60-67
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2234-3156
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605660
  issn: 2234-1900
  databaseCode: KQ8
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVEBS
  databaseName: Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 2234-3156
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605660
  issn: 2234-1900
  databaseCode: ABDBF
  dateStart: 20120901
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2234-3156
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605660
  issn: 2234-1900
  databaseCode: DIK
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2234-3156
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605660
  issn: 2234-1900
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVERR
  databaseName: KoreaMed Open Access
  customDbUrl:
  eissn: 2234-3156
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605660
  issn: 2234-1900
  databaseCode: 5-W
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://koreamed.org/journals
  providerName: Korean Association of Medical Journal Editors
– providerCode: PRVAQN
  databaseName: PubMed Central (Free e-resource, activated by CARLI)
  customDbUrl:
  eissn: 2234-3156
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605660
  issn: 2234-1900
  databaseCode: RPM
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2234-3156
  dateEnd: 20250630
  omitProxy: true
  ssIdentifier: ssj0000605660
  issn: 2234-1900
  databaseCode: M48
  dateStart: 20120901
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Nb9QwEB2xRUK9oCK-Au3KICRORknsOJtDVVWIqiCVU1fqzVp_wdKSQHaR2H_Qn90ZO7u0aHvKIY6j-I09b-KZZ4B3yinv0fNxIRrHJVIS3oRK8RAE8nFR2MpRgfPZV3U6lV8uqot_-U_DAC62hnZ0ntS0v_rw9_fqCCf8IUWcEwzo--4HBnol5WihAx3BQ_RKJVn42UD106qMrj4WDaNDlBz9YJ40HLd0sQuPaAOimVBd7S13NWr7sI2J_p9QectDnezB44FasuNkC0_ggW-fwvU5guW5IxH_JMDBXLfwLAbCG_FYTs7MMUo-XCeeUzN8iAT8GZo7ZRRFENm8ZWlJi7d-do4OAMOHccawVM21YsiEsbMuVisxS4bVP4Ppyafzj6d8OH2BW1nKJTdFrZwn9RmHa6DJbRkqmzel9aGoZkUQovalqgxxDOVoR1kIP1NeTmaFQWInnsNO27X-JbBgatPI3OBklxJHadJUdZk7Y4PyhXUuA74eZG0HaXI6IeNKY4hC-GjERxM-OuKTwftN-19JlOPelm8RM31p55p0tOn6rdOXvcZo4bMmZSBcYDN4s4ZU4-SiHZNZ67s_C418hgTqkCNm8CJBvHnh2kIyqO-Av2lAL7x7p51_jwLedVEIJOKv7u3zNezSN6Rct33YQWvwB0h-lmYcrXoc_0rdAIO8BTY
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Three-dimensional+dose+reconstruction-based+pretreatment+dosimetric+verification+in+volumetric+modulated+arc+therapy+for+prostate+cancer&rft.jtitle=Radiation+oncology+journal&rft.au=Jeong%2C+Yuri&rft.au=Oh%2C+Jeong+Geun&rft.au=Kang%2C+Jeong+Ku&rft.au=Moon%2C+Sun+Rock&rft.date=2020-03-01&rft.issn=2234-1900&rft.volume=38&rft.issue=1&rft.spage=60&rft_id=info:doi/10.3857%2Froj.2020.00066&rft_id=info%3Apmid%2F32229810&rft.externalDocID=32229810
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-1900&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-1900&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-1900&client=summon